SeroSelectTB

Summary

The performance of a new triage test for active tuberculosis, SeroSelectTB, will be qualified in multi-centre randomised controlled trials at health-posts in South Africa, Tanzania and Ethiopia. Cost effectiveness evaluations will be conducted to support a value proposition to stakeholders and regulatory authorities, and to support commercialization requirements. Consenting adults will provide blood and saliva samples for screening by SeroSelectTB, and sputum collected for routine TB diagnosis by the health services. Clinical and sociodemographic information will be collected. A reliable rapid test will make it possible to identify and selectively treat those with active TB at the local healthcare level. The expected impact includes accurate same-day diagnosis of patients with active TB, reduction of diagnostic delay and TB transmission, and diagnostic cost-savings for patients and healthcare systems in high burden countries.

SeroSelectTB is a multinational project coordinated by the Norwegian Institute of Public Health (Oslo, Norway). Partners include Stellenbosch University and Lateral Flow Laboratories (South Africa), Kilimanjaro Christian Medical University College (Tanzania), Armauer Hansen Research Institute (Ethiopia), KNCV Tuberculosis Foundation (Netherlands), InVivo Biotech Services GmbH (Germany), and Aether Dynamics Consulting & Trading GmbH (Austria).